NASDAQ : BOLD
Boundless Bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 56.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 56.18M |
| Enterprise Value | -16.44M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 22.75M |
| Shares Outstanding | 22.75M |
| Shares Change (YoY) | +0.37% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 3.01% |
| Owned by Institutions (%) | 52.47% |
| Float | 15.78M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.48 |
| Quick Ratio | 9.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -67.86% |
| Return on Assets (ROA) | -32.77% |
| Return on Invested Capital (ROIC) | -34.84% |
| Return on Capital Employed (ROCE) | -100.62% |
| Weighted Average Cost of Capital (WACC) | 6.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.29M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +72.73% |
| 50-Day Moving Average | 2.66 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 46.51 |
| Average Volume (20 Days) | 165,404 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 788,477 |
| Short Previous Month | 778,470 |
| Short % of Shares Out | 3.47% |
| Short % of Float | 5.00% |
| Short Ratio (days to cover) | 4.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -66.38M |
| Pretax Income | -64.01M |
| Net Income | -64.01M |
| EBITDA | -64.23M |
| EBIT | -66.38M |
| Earnings Per Share (EPS) | -$2.86 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 72.63M |
| Total Debt | n/a |
| Net Cash | 72.63M |
| Net Cash Per Share | $3.19 |
| Equity (Book Value) | 65.98M |
| Book Value Per Share | 2.94 |
| Working Capital | 65.88M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -56.25M |
| Capital Expenditures | -485,000 |
| Depreciation & Amortization | 2.16M |
| Net Borrowing | n/a |
| Free Cash Flow | -56.73M |
| FCF Per Share | -$2.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.37% |
| Shareholder Yield | -0.37% |
| Earnings Yield | -115.64% |
| FCF Yield | -100.98% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |